Perhaps, the greatest merit of the Castell et al. [118] study is the demonstration of the effects of MYCMI-6 administration by daily intraperitoneal injection at a dose of 20 mg/kg in vivo, where MYCMI-6 induced massive apoptosis and reduced tumor cell proliferation, tumor microvasculature density, and N-Myc-Max interaction in an N-Myc-dependent mouse xenograft tumor model based on human N-Myc amplified SK-N-DZ neuroblastoma cells, without causing severe side effects. This evidence concerns the gene MAX and neoplasm.